Neuroinflammation in parkinson’s disease animal models: A cell stress response or a step in neurodegeneration?

Current Topics in Behavioral Neurosciences

Volumn 22, Issue , 2014, Pages 237-270

  Cebrián, Carolina ^a   Loike, John D ^a   Sulzer, David ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

Animal models; Lymphocytes; Microglia; Neurodegeneration; Neuroinflammation; Parkinson s disease; Proinflammatory cytokines

Indexed keywords

ALPHA SYNUCLEIN; APOPTOSIS SIGNAL REGULATING KINASE 1; CHEMOKINE RECEPTOR CXCR4; DJ 1 PROTEIN; DOPAMINE TRANSPORTER; DYNORPHIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 3 RECEPTOR; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 7; LEUCINE RICH REPEAT KINASE 2; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDOPAMINE; PARAQUAT; PARKIN; POLYINOSINIC POLYCYTIDYLIC ACID; PROSTAGLANDIN J2; REACTIVE OXYGEN METABOLITE; ROTENONE; STROMAL CELL DERIVED FACTOR 1; UNINDEXED DRUG; VESICULAR MONOAMINE TRANSPORTER;

ANIMAL MODEL; APOPTOSIS; ARTICLE; ASTROCYTE; BEHAVIOR; CELLULAR STRESS RESPONSE; CORPUS STRIATUM; CYTOKINE RESPONSE; DISEASE MODEL; DOPAMINERGIC NERVE CELL; GENETIC MODEL; HUMAN; LYMPHOCYTIC INFILTRATION; MICROGLIA; MPTP-INDUCED PARKINSONISM; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SWIMMING; ANIMAL; COMPARATIVE STUDY; IMMUNOLOGY; INFLAMMATION; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; INFLAMMATION; PARKINSON DISEASE;

EID: 84941052523     PISSN: 18663370     EISSN: 18663389     Source Type: Book Series    
DOI: 10.1007/7854_2014_356     Document Type: Article

References (279)

1. Abeliovich A, Schmitz Y, Fariñas I et al (2000) Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25(1):239-252
2. Akiyama H, McGeer PL (1989) Microglial response to 6-hydroxydopamine-induced substantia nigra lesions. Brain Res 489(2):247-253
3. Alberio T, Lopiano L and Fasano M (2012) Cellular models to investigate biochemical pathways in Parkinson's disease. FEBS J279. doi:10.1111/j.1742-4658.2012.08516.x
4. Ambrosi G, Armentero MT, Levandis G et al (2010) Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease. Brain Res Bull 82(1-2):29-38
5. Armentero MT, Levandis G, Nappi G et al (2006) Peripheral inflammation and neuroprotection: systemic pretreatment with complete Freund's adjuvant reduces 6-hydroxydopamine toxicity in a rodent model of Parkinson's disease. Neurobiol Dis 24(3):492-505
6. Baldereschi M, Inzitari M, Vanni P et al (2008) Pesticide exposure might be a strong risk factor for Parkinson's disease. Ann Neurol 63(1):128
7. Barcia C, Ros CM, Annese V et al (2011) IFN-γ signaling, with the synergistic contribution of TNF-α, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease. Cell Death Dis 2:e142
8. Barkholt P, Sanchez-Guajardo V, Kirik D et al (2012) Long-term polarization of microglia upon α-synuclein overexpression in nonhuman primates. Neuroscience 208:85-96
9. Barnum CJ, Tansey MG (2010) Modeling neuroinflammatory pathogenesis of Parkinson's disease. Prog Brain Res 184:113-132
10. Betarbet R, Sherer TB, MacKenzie G et al (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3(12):1301-1306
11. Bichler Z, Lim HC, Zeng L, Tan EK (2013) Non-motor and motor features in LRRK2 transgenic mice. PLoS One 8(7):e70249
12. Biskup S, Moore DJ, Celsi F et al (2006) Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol 60(5):557-569
13. Blandini F (2013) Neural and immune mechanisms in the pathogenesis of Parkinson's disease. Funct Neurol 28(1):5
14. Bobyn J, Mangano EN, Gandhi A et al (2012) Viral-toxin interactions and Parkinson's disease: poly I: C priming enhanced the neurodegenerative effects of paraquat. J Neuroinflammation 9:86
15. Bové J, Perier C (2012) Neurotoxin-based models of Parkinson's disease. Neuroscience 211:51-76
16. Braak H, Del Tredici K (2010) Pathophysiology of sporadic Parkinson's disease. Fortschr Neurol Psychiatr 78(Suppl 1):2-4
17. Brochard V, Combadière B, Prigent A et al (2009) Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 119 (1):182-192
18. Bronstein DM, Perez-Otano I, Sun V et al (1995) Glia-dependent neurotoxicity and neuroprotection in mesencephalic cultures. Brain Res 704(1):112-116
19. Bungeroth M, Appenzeller S, Regulin A, Völker W et al (2014) Differential aggregation properties of alpha-synuclein isoforms. Neurobiol Aging S0197-4580(14):00201-00202
20. Carvey PM, Chang Q, Lipton JW et al (2003) Prenatal exposure to the bacteriotoxin lipopolysaccharide leads to long-term losses of dopamine neurons in offspring: a potential, new model of Parkinson's disease. Front Biosci 8:826-837
21. Casarejos MJ, Menéndez J, Solano RM et al (2006) Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline. J Neurochem 97(4):934-946
22. Castaño A, Herrera AJ, Cano J et al (1998) Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J Neurochem 70 (4):1584-1592
23. Castaño A, Herrera AJ, Cano J et al (2002) The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF-alpha, IL-1beta and IFN-gamma. J Neurochem 81(1):150-157
24. Cebrián C, Zucca FA, Mauri P et al (2014) MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration. Nat Commun 16(5):3633
25. Chesselet MF (2008) In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease? Exp Neurol 209(1):22-27
26. Choi DY, Liu M, Hunter RL et al (2009) Striatal neuroinflammation promotes Parkinsonism in rats. PLoS One 4(5):e5482
27. Chung YC, Kim SR, Jin BK (2010) Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease. J Immunol 185(2):1230-1237
28. Cicchetti F, Brownell AL, Williams K et al (2002) Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci 15(6):991-998
29. Cicchetti F, Drouin-Ouellet J, Gross RE (2009) Environmental toxins and Parkinson's disease: what have we learned from pesticide-induced animal models? Trends Pharmacol Sci 30 (9):475-483
30. Cicchetti F, Lapointe N, Roberge-Tremblay A et al (2005) Systemic exposure to paraquat and maneb models early Parkinson's disease in young adult rats. Neurobiol Dis 20(2):360-371
31. Clark IE, Dodson MW, Jiang C et al (2006) Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 441:1162-1166
32. Collins LM, Toulouse A, Connor TJ et al (2012) Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease. Neuropharmacology 62 (7):2154-2168
33. Conway KA, Harper JD, Lansbury PT Jr (2000a) Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 39 (10):2552-2563
34. Conway KA, Lee SJ, Rochet JC et al (2000b) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA 97(2):571-576
35. Correia Guedes L, Ferreira JJ, Rosa MM et al (2010) Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: a systematic review. Parkinsonism Relat Disord 16 (4):237-242
36. Corti O, Brice A (2013) Mitochondrial quality control turns out to be the principal suspect in parkin and PINK1-related autosomal recessive Parkinson's disease. Curr Opin Neurobiol 23:100-108
37. Couch Y, Alvarez-Erviti L, Sibson NR et al (2011) The acute inflammatory response to intranigral α-synuclein differs significantly from intranigral lipopolysaccharide and is exacerbated by peripheral inflammation. J Neuroinflammation 8:166
38. Cuervo AM, Stefanis L, Fredenburg R et al (2004) Impaired degradation of mutant alphasynuclein by chaperone-mediated autophagy. Science 305(5688):1292-1295
39. Członkowska A, Kohutnicka M, Kurkowska-Jastrzebska I et al (1996) Microglial reaction in MPTP (1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine) induced Parkinson's disease mice model. Neurodegeneration 5(2):137-143
40. Daher JP, Volpicelli-Daley LA, Blackburn JP et al (2014) Abrogation of α-synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats. Proc Natl Acad Sci USA (in press)
41. Damier P, Hirsch EC, Zhang P et al (1993) Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience 52(1):1-6
42. Danoy P, Pryce K, Hadler J et al (2010) Association of variants at 1q32 and STAT3 with ankylosing spondylitis suggests genetic overlap with Crohn's disease. PLoS Genet 6(12): e1001195
43. Dauer W, Kholodilov N, Vila M et al (2002) Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci USA 99(22):14524-14529
44. Davis GC, Williams AC, Markey SP et al (1979) Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1(3):249-254
45. Dawson TM, Ko HS, Dawson VL (2010) Genetic animal models of Parkinson's disease. Neuron 66(5):646-661
46. de Meira Santos Lima M, Braga Reksidler A, Marques Zanata S et al (2006) Different parkinsonism models produce a time-dependent induction of COX-2 in the substantia nigra of rats. Brain Res 1101(1):117-125
47. De Pablos RM, Herrera AJ, Villarán RF et al (2005) Dopamine-dependent neurotoxicity of lipopolysaccharide in substantia nigra. FASEB J 19(3):407-409
48. Del Tredici K, Braak H (2012) Lewy pathology and neurodegeneration in premotor Parkinson's disease. Mov Disord 27(5):597-607
49. Deleidi M, Hallett PJ, Koprich JB et al (2010) The Toll-like receptor-3 agonist polyinosinic: polycytidylic acid triggers nigrostriatal dopaminergic degeneration. J Neurosci 30 (48):16091-16101
50. Deng H, Yuan L (2014) Genetic variants and animal models in SNCA and Parkinson disease. Ageing Res Rev. 2014 Apr 21. pii: S1568-1637(14):00048-8
51. Desai VG, Feuers RJ, Hart RW et al (1996) MPP(+)-induced neurotoxicity in mouse is agedependent: evidenced by the selective inhibition of complexes of electron transport. Brain Res 715(1-2):1-8
52. Drolet RE, Sanders JM, Kern JT (2011) Leucine-rich repeat kinase 2 (LRRK2) cellular biology: a review of recent advances in identifying physiological substrates and cellular functions. J Neurogenet 25(4):140-151
53. Dusonchet J, Kochubey O, Stafa K et al (2011) A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2. J Neurosci 31(3):907-912
54. Dutta G, Zhang P, Liu B (2008) The lipopolysaccharide Parkinson's disease animal model: mechanistic studies and drug discovery. Fundam Clin Pharmacol 22(5):453-464
55. Dzamko N, Inesta-Vaquera F, Zhang J et al (2012) The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling. PLoS One 7(6):e39132
56. Emmer KL, Waxman EA, Covy JP et al (2011) E46K human alpha-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent, detrimental motor impairment. J Biol Chem 286(40):35104-35118
57. Engelhardt B, Coisne C (2011) Fluids and barriers of the CNS establish immune privilege by confining immune surveillance to a two-walled castle moat surrounding the CNS castle. Fluids Barriers CNS 8(1):4
58. Eslamboli A, Romero-Ramos M, Burger C, Bjorklund T et al (2007) Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. Brain 130(Pt 3):799-815
59. Esposito E, Impellizzeri D, Mazzon E et al (2012) Neuroprotective activities of palmitoylethanolamide in an animal model of Parkinson's disease. PLoS One 7(8):e41880
60. Fang F, Wirdefeldt K, Jacks A et al (2012) CNS infections, sepsis and risk of Parkinson's disease. Int J Epidemiol 41(4):1042-1049
61. Fleming SM, Salcedo J, Fernagut PO et al (2004) Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J Neurosci 24(42):9434-9440
62. Foix C, Nicolesco J (1925) Anatomie cérébrale. Les noyaux gris centraux et la región Mésencéphalo-sous-optique., Suivi d'un apéndice sur l'anatomie pathologique de la maladie de Parkinson. Masson et Cie, eds (Paris), 508-538
63. Fortin DL, Nemani VM, Voglmaier SM et al (2005) Neural activity controls the synaptic accumulation of alpha-synuclein. J Neurosci 25(47):10913-10921
64. Franzén B, Duvefelt K, Jonsson C, Engelhardt B et al (2003) Gene and protein expression profiling of human cerebral endothelial cells activated with tumor necrosis factor-alpha. Brain Res Mol Brain Res 115(2):130-146
65. Frank-Cannon TC, Alto LT, McAlpine FE et al (2009) Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener 16(4):47
66. Frank-Cannon TC, Tran T, Ruhn KA et al (2008) Parkin deficiency increases vulnerability to inflammation-related nigral degeneration. J Neurosci 28(43):10825-10834
67. Fulceri F, Biagioni F, Lenzi P et al (2006) Nigrostriatal damage with 6-OHDA: validation of routinely applied procedures. Ann N Y Acad Sci 1074:344-348
68. Gao JJ, Diesl V, Wittmann T et al (2002a) Regulation of gene expression in mouse macrophages stimulated with bacterial CpG-DNA and lipopolysaccharide. J Leukoc Biol 72(6):1234-1245
69. Gao HM, Hong JS, Zhang W et al (2002b) Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 22(3):782-790
70. Gao HM, Kotzbauer PT, Uryu K et al (2008) Neuroinflammation and oxidation/nitration of alphasynuclein linked to dopaminergic neurodegeneration. J Neurosci 28(30):7687-7698
71. Gao HM, Liu B, Hong JS (2003) Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 23(15):6181-6187
72. Gao HM, Zhang F, Zhou H et al (2011) Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease. Environ Health Perspect 119(6):807-814
73. Gardet A, Benita Y, Li C et al (2010) LRRK2 is involved in the IFN-gamma response and host response to pathogens. J Immunol 185(9):5577-5585
74. Gayle DA, Ling Z, Tong C et al (2002) Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-alpha, interleukin-1beta, and nitric oxide. Brain Res Dev Brain Res 133(1):27-35
75. Geng Y, Fang M, Wang J et al (2011) Triptolide down-regulates COX-2 expression and PGE2 release by suppressing the activity of NF-κB and MAP kinases in lipopolysaccharide-treated PC12 cells. Phytother Res 26(3):337-343
76. George S, van den Buuse M, San Mok S, Masters CL et al (2008) Alpha-synuclein transgenic mice exhibit reduced anxiety-like behaviour. Exp Neurol 210(2):788-792
77. Ghosh A, Kanthasamy A, Joseph J et al (2012) Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson's disease. J Neuroinflammation 9:241
78. Giasson BI, Duda JE, Quinn SM et al (2002) Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 34(4):521-533
79. Gillardon F, Schmid R, Draheim H (2012) Parkinson's disease-linked leucine-rich repeat kinase 2 (R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity. Neuroscience 208:41-48
80. Gispert S, Ricciardi F, Kurz A et al (2009) Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration. PloS ONE 4:e5777
81. Glinka Y, Gassen M, Youdim MB (1997) Mechanism of 6-hydroxydopamine neurotoxicity. J Neural Transm Suppl 50:55-66
82. Goes AT, Souza LC, Filho CB et al (2014) Neuroprotective effects of swimming training in a mouse model of Parkinson's disease induced by 6-hydroxydopamine. Neuroscience 256C:61-71
83. Goldberg MS, Fleming SM, Palacino JJ et al (2003) Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem 278:43628-43635
84. Gombash SE, Manfredsson FP, Kemp CJ et al (2013) Morphological and behavioral impact of AAV2/5-mediated overexpression of human wildtype alpha-synuclein in the rat nigrostriatal system. PLoS One 8(11):e81426
85. Gomez-Isla T, Irizarry MC, Mariash A, Cheung B et al (2003) Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice. Neurobiol Aging 24(2):245-258
86. Gomide V, Bibancos T, Chadi G (2005) Dopamine cell morphology and glial cell hypertrophy and process branching in the nigrostriatal system after striatal 6-OHDA analyzed by specific sterological tools. Int J Neurosci 115(4):557-582
87. González H, Contreras F, Prado C, Elgueta D et al (2013) Dopamine receptor D3 expressed on CD4+ T cells favors neurodegeneration of dopaminergic neurons during Parkinson's disease. J Immunol 190(10):5048-5056
88. Graham DR, Sidhu A (2010) Mice expressing the A53T mutant form of human alphasynuclein exhibit hyperactivity and reduced anxiety-like behavior. J Neurosci Res 88 (8):1777-1783
89. Greggio E, Jain S, Kingsbury A et al (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 23(2):329-341
90. Grünblatt E, Mandel S, Maor G et al (2001) Gene expression analysis in N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R-apomorphine. J Neurochem 78(1):1-12
91. Guo JL, Covell DJ, Daniels JP et al (2013) Distinct α-synuclein strains differentially promote tau inclusions in neurons. Cell 154(1):103-117
92. Gupta A, Kumar A, Kulkarni SK (2011) Targeting oxidative stress, mitochondrial dysfunction and neuroinflammatory signaling by selective cyclooxygenase (COX)-2 inhibitors mitigates MPTP-induced neurotoxicity in mice. Prog Neuropsychopharmacol Biol Psychiatry 35 (4):974-981
93. Gupta SP, Patel S, Yadav S et al (2010) Involvement of nitric oxide in maneb-and paraquatinduced Parkinson's disease phenotype in mouse: is there any link with lipid peroxidation? Neurochem Res 35(8):1206-1213
94. Hancock DB, Martin ER, Mayhew GM et al (2008) Pesticide exposure and risk of Parkinson's disease: a family-based case-control study. BMC Neurol 8:6. doi:10.1186/1471-2377-8-6
95. Harkavyi A, Abuirmeileh A, Lever R et al (2008) Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J Neuroinflammation 5:19
96. Harms AS, Barnum CJ, Ruhn KA et al (2011) Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson's disease. Mol Ther 19(1):46-52
97. Harms AS, Cao S, Rowse AL et al (2013) MHCII is required for α-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration. J Neurosci 33 (23):9592-9600
98. Hattori N, Kitada T, Matsumine H et al (1998) Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: evidence for variable homozygous deletions in the Parkin gene in affected individuals. Ann Neurol 44(6):935-941
99. He Y, Appel S, Le W (2001) Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res 909(1-2):187-193
100. Healy DG, Falchi M, O'Sullivan SS et al (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 7 (7):583-590
101. Hennis MR, Marvin MA, Taylor CM, Goldberg MS (2014) Surprising behavioral and neurochemical enhancements in mice with combined mutations linked to Parkinson's disease. Neurobiol Dis 62:113-123
102. Henry J, Smeyne RJ, Jang H et al (2010) Parkinsonism and neurological manifestations of influenza throughout the 20th and 21st centuries. Parkinsonism Relat Disord 16(9):566-571
103. Hernández-Romero MC, Argüelles S, Villarán RF et al (2008) Simvastatin prevents the inflammatory process and the dopaminergic degeneration induced by the intranigral injection of lipopolysaccharide. J Neurochem 105(2):445-459
104. Herva ME, Zibaee S, Fraser G, Barker RA et al (2014) Anti-amyloid compounds inhibit alphasynuclein aggregation induced by Protein Misfolding Cyclic Amplification (PMCA). J Biol Chem (in press)
105. Hinkle KM, Yue M, Behrouz B et al (2012) LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors. Mol Neurodegener 7:25
106. Hirsch EC, Hunot S (2009) Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 8(4):382-397
107. Hoban DB, Connaughton E, Connaughton C et al (2013) Further characterisation of the LPS model of Parkinson's disease: a comparison of intra-nigral and intra-striatal lipopolysaccharide administration on motor function, microgliosis and nigrostriatal neurodegeneration in the rat. Brain Behav Immun 27(1):91-100
108. Hoepken HH, Gispert S, Morales B et al (2007) Mitochondrial dysfunction, peroxidation damage and changes in glutathione metabolism in PARK6. Neurobiol Dis 25:401-411
109. Hunter RL, Cheng B, Choi DY et al (2009) Intrastriatal lipopolysaccharide injection induces parkinsonism in C57/B6 mice. J Neurosci Res 87(8):1913-1921
110. Iravani MM, Leung CC, Sadeghian M et al (2005) The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation. Eur J Neurosci 22(2):317-330
111. Itier JM, Ibanez P, Mena MA et al (2003) Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum Mol Genet 12:2277-2291
112. Izumi Y, Ezumi M, Takada-Takatori Y, Akaike A et al (2014) Endogenous dopamine is involved in the herbicide paraquat-induced dopaminergic cell death. Toxicol Sci (in press)
113. Janezic S, Threlfell S, Dodson PD, Dowie MJ et al (2013) Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model. Proc Natl Acad Sci USA 110 (42):E4016-E4025
114. Jankovic J (2008) Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79(4):368-376
115. Johnston LC, Su X, Maguire-Zeiss K et al (2008) Human interleukin-10 gene transfer is protective in a rat model of Parkinson's disease. Mol Ther 16(8):1392-1399
116. Jung BD, Shin EJ, Nguyen XK et al (2010) Potentiation of methamphetamine neurotoxicity by intrastriatal lipopolysaccharide administration. Neurochem Int 56(2):229-244
117. Kahle PJ, Waak J, Gasser T (2009) DJ-1 and prevention of oxidative stress in Parkinson's disease and other age-related disorders. Free Radic Biol Med 47(10):1354-1361
118. Kamel F, Tanner C, Umbach D et al (2007) Pesticide exposure and self-reported Parkinson's disease in the agricultural health study. Am J Epidemiol 165(4):364-374
119. Kasten M, Klein C (2013) The many faces of alpha-synuclein mutations. Mov Disord 28 (6):697-701
120. Kim B, Yang MS, Choi D et al (2012) Impaired inflammatory responses in murine Lrrk2-knockdown brain microglia. PLoS One 7(4):e34693
121. Kirik D, Annett LE, Burger C et al (2003) Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proc Natl Acad Sci USA 100(5):2884-2889
122. Kirik D, Rosenblad C, Burger C et al (2002) Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci 22(7):2780-2791
123. Kitada T, Asakawa S, Hattori N et al (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392(6676):605-608
124. Kitada T, Pisani A, Porter DR et al (2007) Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice. Proc Natl Acad Sci 104:11441-11446
125. Klementiev B, Li S, Korshunova I et al (2014) Anti-inflammatory properties of a novel peptide interleukin 1 receptor antagonist. J Neuroinflammation 11:27
126. Klintworth H, Garden G, Xia Z (2009) Rotenone and paraquat do not directly activate microglia or induce inflammatory cytokine release. Neurosci Lett 462(1):1-5
127. Ko HS, von Coelln R, Sriram SR et al (2005) Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, pp38/JTV-1, leads to catecholaminergic cell death. J Neurosci 25:7968-7978
128. Kopin IJ (1987) MPTP: an industrial chemical and contaminant of illicit narcotics stimulates a new era in research on Parkinson's disease. Environ Health Perspect 75:45-51
129. Koprich JB, Reske-Nielsen C, Mithal P et al (2008) Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease. J Neuroinflammation 5:8
130. Kortekaas R, Leenders KL, van Oostrom JC et al (2005) Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 57(2):176-179
131. Krüger R, Kuhn W, Müller T et al (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Ann Neurol 18(2):106-108
132. Kunikowska G, Jenner P (2001) 6-Hydroxydopamine-lesioning of the nigrostriatal pathway in rats alters basal ganglia mRNA for copper, zinc-and manganese-superoxide dismutase, but not glutathione peroxidase. Brain Res 922(1):51-64
133. Kurkowska-Jastrzebska I, Wrońska A, Kohutnicka M et al (1999) The inflammatory reaction following 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine intoxication in mouse. Exp Neurol 156(1):50-61
134. L'Episcopo F, Tirolo C, Caniglia S et al (2010) Combining nitric oxide release with antiinflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine model of Parkinson's disease. J Neuroinflammation. 7:83
135. L'Episcopo F, Tirolo C, Testa N et al (2011) Switching the microglial harmful phenotype promotes lifelong restoration of subtantia nigra dopaminergic neurons from inflammatory neurodegeneration in aged mice. Rejuvenation Res 14(4):411-424
136. Langston JW, Forno LS, Tetrud J et al (1999) Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine exposure. Ann Neurol 46(4):598-605
137. Larsen KE, Schmitz Y, Troyer MD et al (2006) Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J Neurosci 26(46):11915-11922
138. Lee HJ, Chung KC (2012) PINK1 positively regulates IL-1β-mediated signaling through Tollip and IRAK1 modulation. J Neuroinflammation 9:271
139. Lee HJ, Jang SH, Kim H et al (2012a) PINK1 stimulates interleukin-1β-mediated inflammatory signaling via the positive regulation of TRAF6 and TAK1. Cell Mol Life Sci 69 (19):3301-3315
140. Lee BD, Shin JH, VanKampen J et al (2010) Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med 16(9):998-1000
141. Lee MK, Stirling W, Xu Y et al (2002) Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53-> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci U S A. 99(13):8968-8973
142. Lee JK, Tran T, Tansey MG (2009) Neuroinflammation in Parkinson's disease. J Neuroimmune Pharmacol 4(4):419-429
143. Lee KW, Zhao X, Im JY et al (2012b) Apoptosis signal-regulating kinase 1 mediates MPTP toxicity and regulates glial activation. PLoS One 7(1):e29935
144. Li Z, Arnaud L, Rockwell P et al (2004) A single amino acid substitution in a proteasome subunit triggers aggregation of ubiquitinated proteins in stressed neuronal cells. J Neurochem 90 (1):19-28
145. Li M, Dai FR, Du XP et al (2012) Neuroprotection by silencing Inos expression in a 6-OHDA model of Parkinson's disease. J Mol Neurosci 48(1):225-233
146. Li X, Moore DJ, Xiong Y et al (2010a) Reevaluation of phosphorylation sites in the Parkinson disease-associated leucine-rich repeat kinase 2. J Biol Chem 285(38):29569-29576
147. Li X, Patel JC, Wang J et al (2010b) Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J Neurosci 30(5):1788-1797
148. Lin X, Parisiadou L, Sgobio C et al (2012) Conditional expression of Parkinson's disease-related mutant α-synuclein in the midbrain dopaminergic neurons causes progressive neurodegeneration and degradation of transcription factor nuclear receptor related 1. J Neurosci 32 (27):9248-9264
149. Ling ZD, Chang Q, Lipton JW et al (2004) Combined toxicity of prenatal bacterial endotoxin exposure and postnatal 6-hydroxydopamine in the adult rat midbrain. Neuroscience 124 (3):619-628
150. Liou HH, Chen RC, Tsai YF (1996) Effects of paraquat on the substantia nigra of the Wistar rats: neurochemical, histological, and behavioral studies. Toxicol Appl Pharmacol 137(1):34-41
151. Liu M, Bing G (2011) Lipopolysaccharide animal models for Parkinson's disease. Parkinsons Dis 2011:327089
152. Liu J, Guo YM, Hirokawa M et al (2012 ) A synthetic double-stranded RNA, poly I:C, induces a rapid apoptosis of human CD34(+) cells. Exp Hematol 40(4):330-341
153. Liu J, Wang MW, Gu P et al (2010) Microglial activation and age-related dopaminergic neurodegeneration in MPTP-treated SAMP8 mice. Brain Res 1345:213-220
154. Lücking CB, Dürr A, Bonifati V et al (2000) Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med 342(21):1560-1567
155. Luk KC, Kehm V, Carroll J et al (2012a) Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338(6109):949-953
156. Luk KC, Kehm VM, Zhang B et al (2012b) Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J Exp Med 209(5):975-986
157. Machado A, Herrera AJ, Venero JL et al (2011) Inflammatory animal model for Parkinson's disease: the intranigral injection of LPS induced the inflammatory process along with the selective degeneration of nigrostriatal dopaminergic neurons. ISRN Neurol 2011:476158
158. Maekawa T, Mori S, Sasaki Y et al (2012) The I2020T Leucine-rich repeat kinase 2 transgenic mouse exhibits impaired locomotive ability accompanied by dopaminergic neuron abnormalities. Mol Neurodegener 7:15
159. Mangano EN, Litteljohn D, So R et al (2012) Interferon-γ plays a role in paraquat-induced neurodegeneration involving oxidative and proinflammatory pathways. Neurobiol Aging 33 (7):1411-1426
160. Manning-Bog AB, McCormack AL, Li J et al (2002) The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J Biol Chem 277 (3):1641-1644
161. Marinova-Mutafchieva L, Sadeghian M, Broom L et al (2009) Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson's disease. J Neurochem 110(3):966-975
162. Martin LJ, Pan Y, Price AC et al (2006) Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J Neurosci 26(1):41-50
163. Masliah E, Rockenstein E, Veinbergs I et al (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287 (5456):1265-1269
164. Masuda-Suzukake M, Nonaka T, Hosokawa M, Oikawa T et al (2013) Prion-like spreading of pathological α-synuclein in brain. Brain 136(Pt 4):1128-1138
165. Matsui H, Gavinio R, Asano T et al (2013) PINK1 and Parkin complementarily protect dopaminergic neurons in vertebrates. Hum Mol Genet 22(12):2423-2434
166. Mazzio EA, Reams RR, Soliman KF (2004) The role of oxidative stress, impaired glycolysis and mitochondrial respiratory redox failure in the cytotoxic effects of 6-hydroxydopamine in vitro. Brain Res 1-2:24-29
167. McClain JA, Phillips LL, Fillmore HL et al (2009) Increased MMP-3 and CTGF expression during lipopolysaccharide-induced dopaminergic neurodegeneration. Neurosci Lett 460(1):27-31
168. McCoy MK, Martinez TN, Ruhn KA et al (2006) Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. J Neurosci 26(37):9365-9375
169. McCoy MK, Tansey MG (2008) TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation 5:45
170. McGeer PL, Itagaki S, Boyes BE et al (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38(8):1285-1291
171. McGeer PL, McGeer EG (1998) Glial cell reactions in neurodegenerative diseases: pathophysiology and therapeutic interventions. Alzheimer Dis Assoc Disord 12(Suppl 2):S1-S6
172. McGeer PL, Schwab C, Parent A et al (2003) Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine administration. Ann Neurol 54 (5):599-604
173. Mena MA, García de Yébenes J (2008) Glial cells as players in parkinsonism: the "good," the "bad," and the "mysterious" glia. Neuroscientist 14(6):544-560
174. Miake H, Mizusawa H, Iwatsubo T, Hasegawa M (2002) Biochemical characterization of the core structure of alpha-synuclein filaments. J Biol Chem 277(21):19213-19219
175. Miklya I, Goltl P, Hafenscher F et al (2014) The role of parkin in Parkinson's disease. Neuropsychopharmacol Hung 16(2):67-76
176. Miller RM, Kiser GL, Kaysser-Kranich T et al (2007) Wild-type and mutant alphasynuclein induce a multi-component gene expression profile consistent with shared pathophysiology in different transgenic mouse models of PD. Exp Neurol 204(1):421-432
177. Mitra S, Chakrabarti N, Bhattacharyya A (2011) Differential regional expression patterns of α-synuclein, TNF-α, and IL-1β; and variable status of dopaminergic neurotoxicity in mouse brain after Paraquat treatment. J Neuroinflammation 8:163
178. Moehle MS, Webber PJ, Tse T et al (2012) LRRK2 inhibition attenuates microglial inflammatory responses. J Neurosci 32(5):1602-1611
179. Mogi M, Togari A, Tanaka K et al (2000) Increase in level of tumor necrosis factor-alpha in 6-hydroxydopamine-lesioned striatum in rats is suppressed by immunosuppressant FK506. Neurosci Lett 289(3):165-168
180. Mosharov EV, Staal RG, Bové J et al (2006) Alpha-synuclein overexpression increases cytosolic catecholamine concentration. J Neurosci 26(36):9304-9311
181. Mount MP, Lira A, Grimes D et al (2007) Involvement of interferon-gamma in microglialmediated loss of dopaminergic neurons. J Neurosci 27(12):3328-3337
182. Mulcahy P, O'Doherty A, Paucard A, O'Brien T et al (2013) The behavioural and neuropathological impact of intranigral AAV-α-synuclein is exacerbated by systemic infusion of the Parkinson's disease-associated pesticide, rotenone, in rats. Behav Brain Res 15 (243):6-15
183. Na SJ, DiLella AG, Lis EV et al (2010) Molecular profiling of a 6-hydroxydopamine model of Parkinson's disease. Neurochem Res 35(5):761-772
184. Nagatsu T (1997) Isoquinoline neurotoxins in the brain and Parkinson's disease. Neurosci Res 29 (2):99-111
185. Nemani VM, Lu W, Berge V et al (2010) Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65(1):66-79
186. Nguyen TA, Frank-Cannon T, Martinez TN et al (2013) Analysis of inflammation-related nigral degeneration and locomotor function in DJ-1(-/-) mice. J Neuroinflammation 10:50
187. Oestreicher E, Sengstock GJ, Riederer P et al (1994) Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study. Brain Res 660(1):8-18
188. Ohnuki T, Nakamura A, Okuyama S et al (2010) Gene expression profiling in progressively MPTP-lesioned macaques reveals molecular pathways associated with sporadic Parkinson's disease. Brain Res 1346:26-42
189. Olson JK, Miller SD (2004) Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J Immunol 173(6):3916-3924
190. Orenstein SJ, Kuo SH, Tasset I et al (2013) Interplay of LRRK2 with chaperone-mediated autophagy. Nat Neurosci 16(4):394-406
191. Pabon MM, Bachstetter AD, Hudson CE et al (2011) CX3CL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson's disease. J Neuroinflammation 8:9
192. Paisán-Ruíz C, Jain S, Evans EW et al (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44(4):595-600
193. Park B, Yang J, Yun N et al (2010) Proteomic analysis of expression and protein interactions in a 6-hydroxydopamine-induced rat brain lesion model. Neurochem Int 57(1):16-32
194. Paterna JC, Leng A, Weber E et al (2007) DJ-1 and Parkin modulate dopamine-dependent behavior and inhibit MPTP-induced nigral dopamine neuron loss in mice. Mol Ther 15:698-704
195. Perez FA, Curtis WR, Palmiter RD (2005) Parkin-deficient mice are not more sensitive to 6-hydroxydopamine or methamphetamine neurotoxicity. BMC Neurosci 6:71
196. Perumal AS, Gopal VB, Tordzro WK et al (1992) Vitamin E attenuates the toxic effects of 6-hydroxydopamine on free radical scavenging systems in rat brain. Brain Res Bull 29 (5):699-701
197. Pierre SR, Lemmens MA, Figueiredo-Pereira ME (2009) Subchronic infusion of the product of inflammation prostaglandin J2 models sporadic Parkinson's disease in mice. J Neuroinflammation 6:18
198. Polymeropoulos MH, Lavedan C, Leroy E et al (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276(5321):2045-2047
199. Poon HF, Frasier M, Shreve N et al (2005) Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice-a model of familial Parkinson's disease. Neurobiol Dis 18(3):492-498
200. Potashkin JA, Blume SR, Runkle NK (2011) Limitations of animal models of Parkinson's disease. Parkinsons Dis 2011:658083
201. Pott Godoy MC, Tarelli R, Ferrari CC et al (2008) Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease. Brain 131(Pt 7):1880-1894
202. Purisai MG, McCormack AL, Cumine S et al (2007) Microglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration. Neurobiol Dis 25(2):392-400
203. Pycock CJ (1980) Turning behaviour in animals. Neuroscience 5(3):461-514
204. Qin L, Liu Y, Wang T et al (2004) NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. J Biol Chem 279 (2):1415-1421
205. Qin L, Wu X, Block ML et al (2007) Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 55(5):453-462
206. Ransohoff RM, Perry VH (2009) Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol 27:119-145
207. Ransom BR, Kunis DM, Irwin I et al (1987) Astrocytes convert the parkinsonism inducing neurotoxin, MPTP, to its active metabolite, MPP+. Neurosci Lett 75(3):323-328
208. Reynolds AD, Stone DK, Hutter JA, Benner EJ et al (2010) Regulatory T cells attenuate Th17 cellmediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease. J Immunol 184(5):2261-2271
209. Rezai-Zadeh K, Gate D, Town T (2009) CNS infiltration of peripheral immune cells: D-Day for neurodegenerative disease? J Neuroimmune Pharmacol 4(4):462-475
210. Riachi NJ, LaManna JC, Harik SI (1989) Entry of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine into the rat brain. J Pharmacol Exp Ther 249(3):744-748
211. Rochet JC, Outeiro TF, Conway KA et al (2004) Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease. J Mol Neurosci 23(1-2):23-34
212. Rockenstein E, Mallory M, Hashimoto M et al (2002) Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res 68(5):568-578
213. Rockenstein E, Nuber S, Overk CR, Ubhi K et al (2014) Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo. Brain (in press)
214. Ross OA, Braithwaite AT, Skipper LM et al (2008) Genomic investigation of alphasynuclein multiplication and parkinsonism. Ann Neurol 63(6):743-750
215. Roy A, Ghosh A, Jana A et al (2012) Sodium phenylbutyrate controls neuroinflammatory and antioxidant activities and protects dopaminergic neurons in mouse models of Parkinson's disease. PLoS One 7(6):e38113
216. Sadeghian M, Marinova-Mutafchieva L, Broom L et al (2012) Full and partial peroxisome proliferation-activated receptor-γ agonists, but not δ agonist, rescue of dopaminergic neurons in the 6-OHDA parkinsonian model is associated with inhibition of microglial activation and MMP expression. J Neuroimmunol 246(1-2):69-77
217. Salama M, Arias-Carrión O (2011) Natural toxins implicated in the development of Parkinson's disease. Ther Adv Neurol Disord 4(6):361-373
218. Sanchez-Guajardo V, Annibali A, Jensen PH et al (2013a) α-Synuclein vaccination prevents the accumulation of parkinson disease-like pathologic inclusions in striatum in association with regulatory t cell recruitment in a rat model. J Neuropathol Exp Neurol 72(7):624-645
219. Sanchez-Guajardo V, Barnum CJ, Tansey MG et al (2013b) Neuroimmunological processes in Parkinson's disease and their relation to α-synuclein: microglia as the referee between neuronal processes and peripheral immunity. ASN Neuro 5(2):113-139
220. Sanchez-Guajardo V, Febbraro F, Kirik D et al (2010) Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. PLoS One 5(1):e8784
221. Sánchez-Pernaute R, Ferree A, Cooper O et al (2004) Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease. J Neuroinflammation 1(1):6
222. Schober A (2004) Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res 318(1):215-224
223. Sekiyama K, Sugama S, Fujita M et al (2012) Neuroinflammation in Parkinson's disease and related disorders: a lesson from genetically manipulated mouse models of α-synucleinopathies. Parkinsons Dis. doi:10.1155/2012/271732
224. Selvakumar GP, Janakiraman U, Essa MM, Thenmozhi AJ et al (2014) Escin attenuates behavioral impairments, oxidative stress and inflammation in a chronic MPTP/probenecid mouse model of Parkinson's disease. Brain Res S0006-8993(14):00358
225. Shaikh SB, Nicholson LF (2009) Effects of chronic low dose rotenone treatment on human microglial cells. Mol Neurodegener 4:55
226. Sherer TB, Betarbet R, Kim JH et al (2003a) Selective microglial activation in the rat rotenone model of Parkinson's disease. Neurosci Lett 341(2):87-90
227. Sherer TB, Betarbet R, Testa CM et al (2003b) Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci 23(34):10756-10764
228. Sherer TB, Kim JH, Betarbet R et al (2003c) Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp Neurol 179 (1):9-16
229. Shimizu K, Ohtaki K, Matsubara K et al (2001) Carrier-mediated processes in blood-brain barrier penetration and neural uptake of paraquat. Brain Res 906(1-2):135-142
230. Shimoji M, Pagan F, Healton EB et al (2009) CXCR4 and CXCL12 expression is increased in the nigro-striatal system of Parkinson's disease. Neurotox Res 16(3):318-328
231. Shin JH, Ko HS, Kang H et al (2011) PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson's disease. Cell 144:689-702
232. Sindhu KM, Saravanan KS, Mohanakumar KP (2005) Behavioral differences in a rotenoneinduced hemiparkinsonian rat model developed following intranigral or median forebrain bundle infusion. Brain Res 1-2:25-34
233. Singleton AB, Farrer M, Johnson J et al (2003) Alpha-Synuclein locus triplication causes Parkinson's disease. Science 302(5646):841
234. Solano RM, Casarejos MJ, Menéndez-Cuervo J et al (2008) Glial dysfunction in parkin null mice: effects of aging. J Neurosci 28(3):598-611
235. Spillantini MG, Schmidt ML, Lee VM et al (1997) Alpha-synuclein in Lewy bodies. Nature 388 (6645):839-840
236. Sriram K, Matheson JM, Benkovic SA et al (2002) Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. FASEB J 16 (11):1474-1476
237. Staal RG, Hananiya A, Sulzer D (2008) PKC theta activity maintains normal quantal size in chromaffin cells. J Neurochem 105(5):1635-1641
238. Su X, Maguire-Zeiss KA, Giuliano R et al (2008) Synuclein activates microglia in a model of Parkinson's disease. Neurobiol Aging 29(11):1690-1701
239. Sulzer D, Surmeier DJ (2013) Neuronal vulnerability, pathogenesis, and Parkinson's disease. Mov Disord 28(1):41-50
240. Swanson CR, Joers V, Bondarenko V et al (2011) The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys. J Neuroinflammation 8:91
241. Tanaka S, Ishii A, Ohtaki H et al (2013) Activation of microglia induces symptoms of Parkinson's disease in wild-type, but not in IL-1 knockout mice. J Neuroinflammation 10(1):143
242. Tansey MG, Goldberg MS (2010) Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 37(3):510-518
243. Taylor JM, Main BS, Crack PJ (2013) Neuroinflammation and oxidative stress: co-conspirators in the pathology of Parkinson's disease. Neurochem Int 62(5):803-819
244. Theodore S, Cao S, McLean PJ et al (2008) Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J Neuropathol Exp Neurol 67(12):1149-1158
245. Thomas B, von Coelln R, Mandir AS et al (2007) MPTP and DSP-4 susceptibility of substantia nigra and locus coeruleus catecholaminergic neurons in mice is independent of parkin activity. Neurobiol Dis 26:312-322
246. Thornton E, Vink R (2012) Treatment with a substance P receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early Parkinson's disease. PLoS One 7(4): e34138
247. Tobón-Velasco JC, Limón-Pacheco JH, Orozco-Ibarra M, Macías-Silva M et al (2013) 6-OHDAinduced apoptosis and mitochondrial dysfunction are mediated by early modulation of intracellular signals and interaction of Nrf2 and NF-κB factors. Toxicology 8(304):109-119
248. Tofaris GK, Garcia Reitböck P, Humby T et al (2006) Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alphasynuclein( 1-120): implications for Lewy body disorders. J Neurosci v26(15):3942-50
249. Tomás-Camardiel M, Venero JL, de Pablos RM et al (2004) In vivo expression of aquaporin-4 by reactive microglia. J Neurochem 91(4):891-899
250. Tran TA, Nguyen AD, Chang J et al (2011) Lipopolysaccharide and tumor necrosis factor regulate Parkin expression via nuclear factor-kappa B. PLoS One 6(8):e23660
251. Tufekci KU, Genc S, Genc K (2011) The endotoxin-induced neuroinflammation model of Parkinson's disease. Parkinsons Dis 2011:487450
252. Tufekci KU, Meuwissen R, Genc S et al (2012) Inflammation in Parkinson's disease. Adv Protein Chem Struct Biol. doi:10.1016/B978-0-12-398314-5.00004-0
253. Ulusoy A, Decressac M, Kirik D et al (2010) Viral vector-mediated overexpression of α-synuclein as a progressive model of Parkinson's disease. Prog Brain Res 184:89-111
254. Unger EL, Eve DJ, Perez XA et al (2006) Locomotor hyperactivity and alterations in dopamine neurotransmission are associated with overexpression of A53T mutant human alpha-synuclein in mice. Neurobiol Dis. 21(2):431-443
255. Valente EM, Abou-Sleiman PM, Caputo V et al (2004) Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304:1158-1160
256. Vázquez-Claverie M, Garrido-Gil P, San Sebastián W et al (2009) Acute and chronic 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine administrations elicit similar microglial activation in the substantia nigra of monkeys. J Neuropathol Exp Neurol 68(9):977-984
257. Volpicelli-Daley LA, Luk KC, Patel TP et al (2011) Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72(1):57-71
258. von Coelln R, Kügler S, Bähr M, Weller M et al (2001) Rescue from death but not from functional impairment: caspase inhibition protects dopaminergic cells against 6-hydroxydopamineinduced apoptosis but not against the loss of their terminals. J Neurochem 77(1):263-273
259. Von Coelln R, Thomas B, Savitt JM et al (2004) Loss of locus coeruleus neurons and reduced startle in parkin null mice. Proc Natl Acad Sci 101:10744-10749
260. Wachter B, Schürger S, Rolinger J et al (2010) Effect of 6-hydroxydopamine (6-OHDA) on proliferation of glial cells in the rat cortex and striatum: evidence for de-differentiation of resident astrocytes. Cell Tissue Res. 342(2):147-160
261. Wang AL, Liou YM, Pawlak CR et al (2010) Involvement of NMDA receptors in both MPTPinduced neuroinflammation and deficits in episodic-like memory in Wistar rats. Behav Brain Res 208(1):38-46
262. Wang Q, Shin EJ, Nguyen XK et al (2012) Endogenous dynorphin protects against neurotoxinelicited nigrostriatal dopaminergic neuron damage and motor deficits in mice. J Neuroinflammation 9:124
263. Wang XJ, Zhang S, Yan ZQ et al (2011) Impaired CD200-CD200R-mediated microglia silencing enhances midbrain dopaminergic neurodegeneration: roles of aging, superoxide, NADPH oxidase, and p38 MAPK. Free Radic Biol Med 50(9):1094-1106
264. Watson MB, Richter F, Lee SK et al (2012) Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein. Exp Neurol 237(2):318-334
265. Wilms H, Rosenstiel P, Romero-Ramos M et al (2009) Suppression of MAP kinases inhibits microglial activation and attenuates neuronal cell death induced by alpha-synuclein protofibrils. Int J Immunopathol Pharmacol 22(4):897-909
266. Wu SY, Wang TF, Yu L et al (2011) Running exercise protects the substantia nigra dopaminergic neurons against inflammation-induced degeneration via the activation of BDNF signaling pathway. Brain Behav Immun 25(1):135-146
267. Yadav S, Gupta SP, Srivastava G et al (2012) Role of secondary mediators in caffeine-mediated neuroprotection in maneb-and paraquat-induced Parkinson's disease phenotype in the mouse. Neurochem Res 37(4):875-884
268. Yasuda Y, Shimoda T, Uno K et al (2008) The effects of MPTP on the activation of microglia/ astrocytes and cytokine/chemokine levels in different mice strains. J Neuroimmunol 204 (1-2):43-51
269. Yu Z, Xu X, Xiang Z et al (2010) Nitrated alpha-synuclein induces the loss of dopaminergic neurons in the substantia nigra of rats. PLoS One 5(4):e9956
270. Zarranz JJ, Alegre J, Gómez-Esteban JC et al (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55(2):164-173
271. Zhang ZJ, Cheang LC, Wang MW et al (2011a) Ethanolic extract of fructus Alpinia oxyphylla protects against 6-hydroxydopamine-induced damage of PC12 cells in vitro and dopaminergic neurons in zebrafish. Cell Mol Neurobiol 32(1):27-40
272. Zhang S, Wang XJ, Tian LP et al (2011b) CD200-CD200R dysfunction exacerbates microglial activation and dopaminergic neurodegeneration in a rat model of Parkinson's disease. J Neuroinflammation 8:154
273. Zhang W, Phillips K, Wielgus et al (2011c) Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson's disease. Neurotox Res 19:63-72
274. Zhang Z, Zhang K, Du X et al (2012) Neuroprotection of desferrioxamine in lipopolysaccharideinduced nigrostriatal dopamine neuron degeneration. Mol Med Rep 5(2):562-566
275. Zhou H, Falkenburger BH, Schulz JB et al (2007a) Silencing of the Pink1 gene expression by conditional RNAi does not induce dopaminergic neuron death in mice. Int J Biol Sci 3:242-250
276. Zhou F, Wu JY, Sun XL et al (2007b) Iptakalim alleviates rotenone-induced degeneration of dopaminergic neurons through inhibiting microglia-mediated neuroinflammation. Neuropsychopharmacology 32(12):2570-2580
277. Zhou H, Huang C, Tong J et al (2011) Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake. Int J Biol Sci 7(6):753-761
278. Zhou F, Yao HH, Wu JY et al (2008) Opening of microglial K(ATP) channels inhibits rotenoneinduced neuroinflammation. J Cell Mol Med 12(5A):1559-1570
279. Zimprich A, Biskup S, Leitner P et al (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44(4):601-607